The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Abstract
Purpose: To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. Methods: An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines previously published by this group in the Journal of Clinical Oncology in 1998. MEDLINE searches were performed and the relevant literature published since 1998 was reviewed by all panel members. The treatment recommendations and algorithm were revised by panel consensus. Results: A recent review of early toxic deaths occurring in two National Cancer Institute-sponsored cooperative group trials of irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the recognition of a life-threatening gastrointestinal syndrome and highlighted the need for vigilant monitoring and aggressive therapy for this serious complication. Loperamide remains the standard therapy for uncomplicated cases. However, the revised guidelines reflect the need for recognition of the early warning signs of complicated cases of diarrhea and the need for early and aggressive management, including the addition of antibiotics. Management of radiation-induced diarrhea is similar but may not require hospitalization, and chronic low- to intermediate-grade symptoms can be managed with continued loperamide. Conclusion: With vigilant monitoring and aggressive therapy for cancer treatment-induced diarrhea, particularly in patients with early warning signs of severe complications, morbidity and mortality may be reduced.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Self-citationRubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., & Anthony, L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.600 · Cited by 389
Self-citationLeichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., & Mangalik, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1303 · Cited by 359
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1128 · Cited by 352
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344
Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea
Abigerges, D., Armand, J.-P., Chabot, G. G., Costa, L. D., Fadel, E., Cote, C., Herait, P., & Gandia, D. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.6.446 · Cited by 248
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Wadler, S., Benson, A. B., Engelking, C., Catalano, R., Field, M., Kornblau, S. M., Mitchell, E., Rubin, J., Trotta, P., & Vokes, E. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3169 · Cited by 164
Self-citation
Cited by
Stewart, F. A., Akleyev, A. V., Hauer-Jensen, M., Hendry, J. H., Kleiman, N. J., MacVittie, T. J., Aleman, B. M., Edgar, A. B., Mabuchi, K., Muirhead, C. R., et al. (2012) · Annals of the ICRP · doi:10.1016/j.icrp.2012.02.001 · Cited by 1,604
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Stein, A., Voigt, W., & Jordan, K. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009355164 · Cited by 431
“The treatment of CID includes nonpharmacologic and pharmacologic interventions to control diarrhea and careful serial evaluation to rule out significant volume depletion or comorbidities that would require specific intervention or hospitalization [Benson et al. 2004; Maroun et al. 2007].”
BackgroundMethodInfluentialTouchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., Le Vacon, F., & de La Cochetière, M. F. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12878 · Cited by 425
Rugo, H. S., Bardia, A., Marmé, F., Cortes, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Pardo, P. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01002 · Cited by 316
Management of adverse events associated with idelalisib treatment: expert panel opinion
Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., Li, D., O’Brien, S. M., Pagel, J. M., Poleski, M. H., et al. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1022770 · Cited by 273
Systematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View
Xavier, J. B., Young, V. B., Skufca, J., Ginty, F., Testerman, T., Pearson, A. T., Macklin, P., Mitchell, A., Shmulevich, I., Xie, L., et al. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.01.004 · Cited by 272
Guidance on the management of diarrhoea during cancer chemotherapy
Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., Wedlake, L., Bridgewater, J., Glynne-Jones, R., Allum, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70006-3 · Cited by 257
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation
Lee, C. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3751 · Cited by 224
Review article: the management of hepatocellular carcinoma
CABRERA, R., & NELSON, D. R. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04200.x · Cited by 222
Napabucasin: an update on the first-in-class cancer stemness inhibitor
Hubbard, J. M., & Grothey, A. (2017) · Drugs · doi:10.1007/s40265-017-0759-4 · Cited by 157
Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer
Banna, G. L., Torino, F., Marletta, F., Santagati, M., Salemi, R., Cannarozzo, E., Falzone, L., Ferraù, F., & Libra, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00603 · Cited by 150
Management of toxicity to isoform α-specific PI3K inhibitors
Nunnery, S. E., & Mayer, I. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz440 · Cited by 137
Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model
Huang, T.-Y., Chu, H.-C., Lin, Y.-L., Ho, W.-H., Hou, H.-S., Chao, Y.-C., & Liao, C.-L. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.041 · Cited by 59
Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health
Mani, S., Boelsterli, U. A., & Redinbo, M. R. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140007 · Cited by 48
Wang, L., Wang, X., Zhang, G., Ma, Y., Zhang, Q., Li, Z., Ran, J., Hou, X., Geng, Y., Yang, Z., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01899-y · Cited by 48
Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL)
Damery, E., Solimando, D. A., & Waddell, J. A. (2016) · Hospital Pharmacy · doi:10.1310/hpj5108-628 · Cited by 7
Metadata
- Authors
- Benson, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., McCallum, R., Mitchell, E. P., O'Dorisio, T. M., Vokes, E. E., & Wadler, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14
- Pages
- 2918-2926
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097257602
- Cited by
- 631
- References
- 24
- FWCI
- 18.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.